⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9051400 | 0.79 | — | — | |
| SCHEMBL14272841 | 0.79 | — | — | |
| SCHEMBL12537059 | 0.72 | — | — | |
| SCHEMBL751660 | 0.67 | — | — | |
| SCHEMBL23169061 | 0.67 | — | — | |
| SCHEMBL9053138 | 0.67 | — | — | |
| SCHEMBL17305279 | 0.67 | PIK3CD (0.37) | — | |
| SCHEMBL5892337 | 0.64 | — | — | |
| SCHEMBL75994 | 0.63 | ALDH1A1 (0.33) | — | |
| SCHEMBL11062017 | 0.62 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3489231-B1 | PIPERAZINE DERIVATIVE | ASTELLAS PHARMA INC (JP) | 2021-06-09 | — | — | EP | disclosed |
| US-10710988-B2 | Piperazine derivative | ASTELLAS PHARMA INC. (JP) | 2020-07-14 | — | — | US | disclosed |
| EP-3333165-B1 | PIPERAZINE DERIVATIVE | ASTELLAS PHARMA INC (JP) | 2019-09-18 | — | — | EP | disclosed |
| US-20190202815-A1 | PIPERAZINE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2019-07-04 | — | — | US | disclosed |
| EP-3489231-A1 | PIPERAZINE DERIVATIVE | Astellas Pharma Inc. (JP) | 2019-05-29 | — | — | EP | disclosed |
| US-10301286-B2 | Piperazine derivative | ASTELLAS PHARMA INC. (JP) | 2019-05-28 | — | — | US | disclosed |
| EP-3333165-A1 | PIPERAZINE DERIVATIVE | Astellas Pharma Inc. (JP) | 2018-06-13 | — | — | EP | disclosed |
| US-9981960-B2 | Pyrrolidine compound and application as melanocortin receptor agonist | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2018-05-29 | — | — | US | disclosed |
| US-9981960-B2 | Pyrrolidine compound and application as melanocortin receptor agonist | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2018-05-29 | — | — | US | disclosed |
| US-20170190697-A1 | NOVEL PYRROLIDINE COMPOUND AND APPLICATION AS MELANOCORTIN RECEPTOR AGONIST | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2017-07-06 | — | — | US | disclosed |
| US-20060128963-A1 | Piperidine derivatives as melanocortin-4 receptor agonists | MERCK SHARP & DOHME CORP. | 2006-06-15 | — | — | US | disclosed |
| US-7015235-B2 | Acylated piperidine derivatives as melanocortin-4 receptor agonists | MERCK & CO., INC. (US) | 2006-03-21 | — | — | US | disclosed |
| US-20060035935-A1 | Acylated piperidine derivatives as melanocortin-4 receptor agonists | GOULET MARK T | 2006-02-16 | — | — | US | disclosed |
| EP-1610789-A1 | BICYCLIC PIPERIDINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR AGONISTS | Merck & Co., Inc. (US) | 2006-01-04 | — | — | EP | disclosed |
| US-20050176772-A1 | Pharmaceutically active compounds | PFIZER INC | 2005-08-11 | — | — | US | disclosed |
| US-20040266821-A1 | Acylated piperidine derivatives as melanocortin-4 receptor agonists | UJJAINWALLA FEROZE | 2004-12-30 | — | — | US | disclosed |
| US-6818658-B2 | TREATING OBESITY, DIABETES, SEXUAL DYSFUNCTION, INCLUDING ERECTILE DYSFUNCTION AND FEMALE SEXUAL DYSFUNCTION. | MERCK & CO., INC. | 2004-11-16 | — | — | US | disclosed |
| WO-2004087159-A1 | BICYCLIC PIPERIDINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR AGONISTS | MERCK & CO., INC. (US) | 2004-10-14 | — | — | WO | disclosed |
| US-20040097546-A1 | Acylated piperidine derivatives as melanocortin-4 receptor agonists | MERCK SHARP & DOHME CORP. | 2004-05-20 | — | — | US | disclosed |
| US-20030225060-A1 | Acylated piperidine derivatives as melanocortin-4 receptor agonists | MERCK SHARP & DOHME CORP. | 2003-12-04 | — | — | US | disclosed |